PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.\', \'Division of Medical Immunology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.\', \'Department of Clinical Research and Department of Biomedicine, University of Basel, Basel, Switzerland.\', \'Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.\', \'Hospital Universitario Dr. José Eleuterio González, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico.\', \'Department of General Practice, Centro Universitário em Saúde do ABC, Santo André, SP, Brazil.\', \'Clinic for Internal Medicine, City Hospital Triemli, Zurich, Switzerland.\', \'Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.\', \'Institute for Infectious Diseases, University of Bern, Bern, Switzerland.\', \'Division of Internal Medicine, University Hospital Basel, Basel, Switzerland. Michael.Osthoff@usb.ch.\', \'Department of Clinical Research and Department of Biomedicine, University of Basel, Basel, Switzerland. Michael.Osthoff@usb.ch.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s13063-020-04976-x
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 33397449
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all